Crohn's drug study cut short: only 18 patients enrolled

NCT ID NCT03961815

First seen Apr 08, 2026 · Last updated Apr 24, 2026 · Updated 4 times

Summary

This study looked at the long-term safety of the drug brazikumab for people with moderate to severe Crohn's disease. It was designed for patients who had already completed or left an earlier study of the same drug. The study was terminated early and only enrolled 18 participants, so the results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Lincoln, California, 95648, United States

  • Research Site

    Clearwater, Florida, 33756, United States

  • Research Site

    Kissimmee, Florida, 34741, United States

  • Research Site

    Lakeland, Florida, 33813, United States

  • Research Site

    Miami, Florida, 33157, United States

  • Research Site

    Miami, Florida, 33165, United States

  • Research Site

    Miami Lakes, Florida, 33016, United States

  • Research Site

    Tampa, Florida, 33626, United States

  • Research Site

    Beachwood, Ohio, 44122, United States

  • Research Site

    Houston, Texas, 77058, United States

  • Research Site

    Hamburg, 20251, Germany

  • Research Site

    Rzeszów, 35-302, Poland

  • Research Site

    Cape Town, 7500, South Africa

  • Research Site

    Plumstead, 7800, South Africa

  • Research Site

    Taichung, 40443, Taiwan

Conditions

Explore the condition pages connected to this study.